An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
出版年份 2019 全文链接
标题
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)
作者
关键词
Biomarkers, Mechanisms of sensitivity, Mechanisms of resistance, Immunotherapy, Immunology, Drug mechanisms
出版物
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-03-13
DOI
10.1186/s40425-019-0541-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy
- (2018) Henning Zelba et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
- (2018) Yannick Simoni et al. NATURE
- The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients
- (2018) Marc Van den Eynde et al. CANCER CELL
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
- (2015) A. S. Mansfield et al. CLINICAL CANCER RESEARCH
- Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data
- (2014) F. Favero et al. ANNALS OF ONCOLOGY
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
- (2013) Q. Ye et al. CLINICAL CANCER RESEARCH
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- A framework for variation discovery and genotyping using next-generation DNA sequencing data
- (2011) Mark A DePristo et al. NATURE GENETICS
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now